Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor
Kizilbash, S.H., El-Khoueiry, A., Lerner, R.E., Ma, P.C., Almubarak, M., Mody, K., Burkard, M.E., Guarino, M., Jenab-Wolcott, J., Sankar, N., Choy, G., Espiritu, L., Zhang, X., Luria, A., Benedetti, FVolume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)31095-9
Date:
October, 2020
File:
PDF, 464 KB
2020